2349 related articles for article (PubMed ID: 15447678)
21. [Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and alpha-synuclein].
Iwatsubo T
Rinsho Shinkeigaku; 1999 Dec; 39(12):1285-6. PubMed ID: 10791099
[TBL] [Abstract][Full Text] [Related]
22. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
[TBL] [Abstract][Full Text] [Related]
23. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
[TBL] [Abstract][Full Text] [Related]
24. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.
Robertson DC; Schmidt O; Ninkina N; Jones PA; Sharkey J; Buchman VL
J Neurochem; 2004 Jun; 89(5):1126-36. PubMed ID: 15147505
[TBL] [Abstract][Full Text] [Related]
25. Synphilin-1 is present in Lewy bodies in Parkinson's disease.
Wakabayashi K; Engelender S; Yoshimoto M; Tsuji S; Ross CA; Takahashi H
Ann Neurol; 2000 Apr; 47(4):521-3. PubMed ID: 10762166
[TBL] [Abstract][Full Text] [Related]
26. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
Mandel RJ; Snyder RO; Leff SE
Exp Neurol; 1999 Nov; 160(1):205-14. PubMed ID: 10630205
[TBL] [Abstract][Full Text] [Related]
27. [The mechanism of Lewy body formation in Parkinson's disease].
Wakabayashi K; Takahashi H
Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441
[TBL] [Abstract][Full Text] [Related]
28. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.
Iwatsubo T
J Neurol; 2003 Oct; 250 Suppl 3():III11-4. PubMed ID: 14579119
[TBL] [Abstract][Full Text] [Related]
29. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A
Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595
[TBL] [Abstract][Full Text] [Related]
30. Viral vectors, animal models and new therapies for Parkinson's disease.
Schneider B; Zufferey R; Aebischer P
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S169-71. PubMed ID: 18585946
[TBL] [Abstract][Full Text] [Related]
31. Synucleins and their relationship to Parkinson's disease.
von Bohlen Und Halbach O
Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
[TBL] [Abstract][Full Text] [Related]
32. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Conway KA; Harper JD; Lansbury PT
Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
[TBL] [Abstract][Full Text] [Related]
33. Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease.
Scherzer CR; Jensen RV; Gullans SR; Feany MB
Hum Mol Genet; 2003 Oct; 12(19):2457-66. PubMed ID: 12915459
[TBL] [Abstract][Full Text] [Related]
34. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.
Eslamboli A; Romero-Ramos M; Burger C; Bjorklund T; Muzyczka N; Mandel RJ; Baker H; Ridley RM; Kirik D
Brain; 2007 Mar; 130(Pt 3):799-815. PubMed ID: 17303591
[TBL] [Abstract][Full Text] [Related]
35. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
36. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ
Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758
[TBL] [Abstract][Full Text] [Related]
37. Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease.
Febbraro F; Sahin G; Farran A; Soares S; Jensen PH; Kirik D; Romero-Ramos M
Neurobiol Dis; 2013 Aug; 56():47-58. PubMed ID: 23567651
[TBL] [Abstract][Full Text] [Related]
38. α-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease.
Chu Y; Mickiewicz AL; Kordower JH
Neurobiol Dis; 2011 Jan; 41(1):71-82. PubMed ID: 20816781
[TBL] [Abstract][Full Text] [Related]
39. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.
Zhang W; Wang T; Pei Z; Miller DS; Wu X; Block ML; Wilson B; Zhang W; Zhou Y; Hong JS; Zhang J
FASEB J; 2005 Apr; 19(6):533-42. PubMed ID: 15791003
[TBL] [Abstract][Full Text] [Related]
40. Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells.
Yamakawa K; Izumi Y; Takeuchi H; Yamamoto N; Kume T; Akaike A; Takahashi R; Shimohama S; Sawada H
Biochem Biophys Res Commun; 2010 Jan; 391(1):129-34. PubMed ID: 19900407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]